Ulcer

Why Rapid-Ease' Herbal Ingredients are Superior to NSAIDs and Other Pain Relievers

Thursday, September 23, 2021 - 1:37pm

Many use over-the-counter drugs like Ibuprofen to manage swelling and other symptoms caused by minor aches, bruises, and other pains.

Key Points: 
  • Many use over-the-counter drugs like Ibuprofen to manage swelling and other symptoms caused by minor aches, bruises, and other pains.
  • The problem is, NSAIDs have come under increased scrutiny in recent years and the results haven't been in their favor.
  • FDA warnings have continued to abound regarding NSAIDs and other pain management meds.
  • NSAIDs aside, even alternative pain relievers like opioids have become a major issue.

MolecuLight i:X® Receives FDA 510(k) Clearance for the Device's Ability to Detect Wounds Likely to Contain Pseudomonas aeruginosa (PA)

Thursday, September 23, 2021 - 11:12am

The i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria.

Key Points: 
  • The i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria.
  • This new FDA clearance supports the ability of the i:X device to increase the clinician's ability to detect the presence of Pseudomonas aeruginosa in wounds using the cyan fluorescence signal.
  • The MolecuLight i:X is the only imaging device that provides real-time information on whether a wound is likely to contain elevated levels of PA (>104 CFU/g).
  • This new FDA clearance recognizes the added benefit of the i:X in visualizing and differentiating Pseudomonas aeruginosa in wounds through the cyan fluorescence signal it produces on the images.

MolecuLight i:X® Receives FDA 510(k) Clearance for the Device's Ability to Detect Wounds Likely to Contain Pseudomonas aeruginosa (PA)

Thursday, September 23, 2021 - 11:12am

TORONTO, Sept. 23, 2021 /PRNewswire/ -- MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received FDA 510(k) clearance for the detection of wounds containing clinically significant levels (>104 CFU/g) of Pseudomonas aeruginosa (PA) for the previously cleared MolecuLight i:X imaging device.  The i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria. This new FDA clearance supports the ability of the i:X device to increase the clinician's ability to detect the presence of Pseudomonas aeruginosa in wounds using the cyan fluorescence signal.  This augmented labeling is based on a detailed retrospective statistical analysis of over 350 patients.

Key Points: 
  • The i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria.
  • This new FDA clearance supports the ability of the i:X device to increase the clinician's ability to detect the presence of Pseudomonas aeruginosa in wounds using the cyan fluorescence signal.
  • The MolecuLight i:X is the only imaging device that provides real-time information on whether a wound is likely to contain elevated levels of PA (>104 CFU/g).
  • This new FDA clearance recognizes the added benefit of the i:X in visualizing and differentiating Pseudomonas aeruginosa in wounds through the cyan fluorescence signal it produces on the images.

Iterative Scopes and Crohn's & Colitis Foundation Announce Partnership to Advance Next-Generation IBD Treatment

Wednesday, September 22, 2021 - 1:30pm

Iterative Scopes intends to collect imaging data from sites participating in IBD Plexus research initiatives to inform its computational models of disease severity scoring algorithms and to further advance its precision medicine initiatives.

Key Points: 
  • Iterative Scopes intends to collect imaging data from sites participating in IBD Plexus research initiatives to inform its computational models of disease severity scoring algorithms and to further advance its precision medicine initiatives.
  • The Crohns & Colitis Foundation works to find cures for patients with IBD and improve patient quality of life, said Caren Heller, MD, MBA, Crohns & Colitis Foundation.
  • Were excited to partner with Iterative Scopes to further leverage the use of artificial intelligence to help improve the treatment of Crohns disease and ulcerative colitis.
  • The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD).

New Study Finds Statistically Significantly Faster Healing Rates for Diabetic Wound Patients Treated with Kerecis Fish Skin

Monday, September 20, 2021 - 9:53pm

A study published in the peer-reviewed journal Wounds reports statistically significantly higher healing rates for diabetic foot ulcers (DFUs) treated with Kerecis Omega3 fish skin compared to DFUs treated with Fibrocol, a collagen-alginate dressing.

Key Points: 
  • A study published in the peer-reviewed journal Wounds reports statistically significantly higher healing rates for diabetic foot ulcers (DFUs) treated with Kerecis Omega3 fish skin compared to DFUs treated with Fibrocol, a collagen-alginate dressing.
  • Of the patients treated with the Kerecis product , 67% had healed after 12 weeks of treatment versus 32% in the control group.
  • These statistically significant results may give new hope to patients suffering from diabetic foot ulcers and other wounds, explained Kerecis founder and CEO Fertram Sigurjonsson.
  • The doctors in this study documented the healing efficacy of the Kerecis Omega3 fish-skin graft technology.

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada

Thursday, September 9, 2021 - 1:30pm

RALEIGH, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has completed the acquisition of U.S. and Canadian rights to ELYXYB™ (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited.

Key Points: 
  • ELYXYB is the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.
  • ELYXYBs unit-dose oral solution makes it convenient for patients to take it immediately upon emergence of acute migraine attacks.
  • BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.
  • ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.

PLx Pharma Inc. to Present at Upcoming Virtual Healthcare Industry Conferences

Thursday, September 9, 2021 - 11:50am

It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.

Key Points: 
  • It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
  • PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products.
  • The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract.
  • To learn more aboutPLx Pharma Inc. and its pipeline, pleasevisit www.plxpharma.com .

Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus

Thursday, September 9, 2021 - 6:00am

The Phase 3 study, which is the first placebo-controlled trial of a BTK inhibitor in pemphigus, enrolled adult patients with moderate-to-severe pemphigus vulgaris or pemphigus foliaceus.

Key Points: 
  • The Phase 3 study, which is the first placebo-controlled trial of a BTK inhibitor in pemphigus, enrolled adult patients with moderate-to-severe pemphigus vulgaris or pemphigus foliaceus.
  • We are committed to investigating rilzabrutinib further and progressing our clinical programs forward to deliver new treatment options for patients.
  • Currently options for the treatment of pemphigus (including pemphigus vulgaris and pemphigus foliaceus) are limited and systemic corticosteroid treatment remains the standard of care.
  • Rilzabrutinib is being investigated in a Phase 3 trial for the treatment of immune thrombocytopenia, a rare blood disorder, and in a Phase 2 study for the autoimmune condition IgG4-related disease.

Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Wednesday, September 8, 2021 - 12:00pm

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13 - 15.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13 - 15.
  • The webcast will be available on the website for 90 days.
  • Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions.
  • The Companys next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.